What is Zacks Research's Estimate for LLY Q2 Earnings?

Eli Lilly and Company (NYSE:LLY - Free Report) - Research analysts at Zacks Research increased their Q2 2025 earnings estimates for shares of Eli Lilly and Company in a report released on Thursday, May 22nd. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $5.53 for the quarter, up from their previous forecast of $5.48. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share. Zacks Research also issued estimates for Eli Lilly and Company's Q3 2025 earnings at $6.30 EPS, Q4 2025 earnings at $6.97 EPS, FY2025 earnings at $22.14 EPS, Q1 2026 earnings at $6.23 EPS, Q2 2026 earnings at $7.21 EPS, Q4 2026 earnings at $9.04 EPS and FY2026 earnings at $30.78 EPS.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the firm earned $2.58 earnings per share. The company's revenue was up 45.2% compared to the same quarter last year.

Other research analysts also recently issued research reports about the stock. Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. UBS Group dropped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Finally, Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Trading Up 0.2%

Shares of NYSE LLY traded up $1.52 during midday trading on Monday, reaching $720.91. The stock had a trading volume of 2,785,058 shares, compared to its average volume of 3,626,568. The firm has a market cap of $683.24 billion, a price-to-earnings ratio of 61.56, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company's 50 day moving average price is $779.13 and its 200 day moving average price is $800.51.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LLY. PNC Financial Services Group Inc. grew its stake in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares during the last quarter. Geode Capital Management LLC lifted its position in Eli Lilly and Company by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock valued at $13,389,651,000 after acquiring an additional 291,875 shares during the last quarter. GAMMA Investing LLC lifted its position in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock valued at $10,495,261,000 after purchasing an additional 81,587 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.83%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.